NRG-GU010 / GUIDANCE — Genomic-risk-adapted therapy in unfavorable intermediate-risk prostate cancer

Phase 3 · Prostate Cancer

Population

Unfavorable intermediate-risk localized prostate cancer.

Primary Endpoint

Metastasis-free survival

Rationale

Intermediate-risk prostate cancer is biologically heterogeneous. The GUIDANCE trial uses a genomic classifier to de-intensify treatment for low-score patients and intensify it for high-score patients.

What It Could Change

Could personalize intermediate-risk prostate cancer therapy by genomic risk rather than clinical features alone.